Nancy Joann Johnson Sells 3,418 Shares of Billiontoone (NASDAQ:BLLN) Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Nancy Joann Johnson sold 3,418 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $99.28, for a total value of $339,339.04. Following the completion of the sale, the insider directly owned 32,482 shares of the company’s stock, valued at $3,224,812.96. The trade was a 9.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nancy Joann Johnson also recently made the following trade(s):

• On Tuesday, June 9th, Nancy Joann Johnson sold 10,582 shares of Billiontoone stock. The stock was sold at an average price of $100.47, for a total value of $1,063,173.54.

Billiontoone Stock Performance

Shares of BLLN stock opened at $99.30 on Friday. The stock has a fifty day moving average of $87.67 and a 200 day moving average of $88.10. Billiontoone, Inc. has a 52 week low of $61.96 and a 52 week high of $138.70. The firm has a market capitalization of $4.57 billion and a price-to-earnings ratio of 180.55. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.33. The business had revenue of $108.39 million during the quarter, compared to analysts’ expectations of $95.81 million. During the same period in the previous year, the business earned ($0.39) EPS. The business’s revenue was up 83.8% compared to the same quarter last year. As a group, research analysts expect that Billiontoone, Inc. will post 0.93 earnings per share for the current year.

Hedge Funds Weigh In On Billiontoone

A number of institutional investors have recently added to or reduced their stakes in BLLN. Adams Street Partners LLC bought a new position in shares of Billiontoone during the fourth quarter valued at $140,063,000. Baillie Gifford & Co. bought a new position in shares of Billiontoone during the fourth quarter valued at $103,786,000. Price T Rowe Associates Inc. MD bought a new position in shares of Billiontoone during the fourth quarter valued at $39,717,000. JPMorgan Chase & Co. bought a new position in shares of Billiontoone during the fourth quarter valued at $32,078,000. Finally, Wasatch Advisors LP bought a new position in shares of Billiontoone during the first quarter valued at $29,179,000.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BLLN. BTIG Research decreased their price objective on Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Weiss Ratings downgraded Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 5th. Wells Fargo & Company decreased their price objective on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a report on Thursday, March 5th. Guggenheim increased their price objective on Billiontoone from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Finally, Wall Street Zen upgraded Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Billiontoone has a consensus rating of “Moderate Buy” and an average target price of $125.29.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.